What is Thrombotic Thrombocytopenic Purpura (TTP)?
TTP is a rare but potentially fatal blood disorder caused by severe deficiency of the plasma protease ADAMTS13 (activity <10%), leading to accumulation of ultra-large von Willebrand factor multimers, excessive platelet aggregation, and microvascular thrombus formation throughout the body, resulting in microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic organ damage. 1, 2
Core Pathophysiology
The disease mechanism centers on ADAMTS13 deficiency, which prevents normal cleavage of ultra-large von Willebrand factor (UL-VWF). Without this enzymatic activity, UL-VWF accumulates on endothelial surfaces and in circulation, triggering excessive platelet adhesion and aggregation. This creates platelet-rich microthrombi in terminal arterioles and capillaries throughout multiple organs, causing the characteristic tissue ischemia and organ damage. 1, 2
ADAMTS13 is produced primarily in hepatic stellate cells and endothelial cells, then released into the bloodstream where it normally cleaves UL-VWF to regulate hemostasis and inflammatory responses. 1
Disease Subtypes
TTP exists in three distinct forms:
Immune TTP (iTTP): Caused by autoantibodies against ADAMTS13, typically presenting in adulthood but can occur in childhood. This is the most common form. 1, 2
Congenital TTP (cTTP): Results from biallelic mutations in the ADAMTS13 gene (previously called Upshaw-Schulman syndrome). More likely diagnosed in neonates and children, though can remain asymptomatic until adulthood. 1, 2
TTP of unknown cause (uTTP): Recently described form where ADAMTS13 deficiency occurs without detectable autoantibodies or genetic mutations. 2
Clinical Presentation
Patients present with severe thrombocytopenia (usually <30 × 10⁹/L), microangiopathic hemolytic anemia, and varying degrees of end-organ damage. 1
Key laboratory findings include:
- Low hemoglobin and hematocrit
- Elevated lactate dehydrogenase (LDH >1500 U/L is a mortality predictor) 3
- Fragmented red blood cells (schistocytes) on blood smear
- Severe thrombocytopenia
Important caveat: Schistocytes are theoretically required for diagnosis but may be absent in some cases. The pathological definition remains somewhat elusive, with some patients showing endothelial swelling and detachment without visible thrombosis. 2
Diagnostic Approach
ADAMTS13 activity measurement is mandatory for diagnosis—activity below 10% confirms TTP. 2
However, the critical clinical challenge is that ADAMTS13 assay results can take several days. Treatment must be initiated immediately upon clinical suspicion before laboratory confirmation, given the potentially devastating complications including mortality. 2
Before ADAMTS13 results are available, use clinical scoring systems:
These assess the likelihood of severe ADAMTS13 deficiency and guide early treatment decisions.
Historical Context and Prognosis
First described by pathologist Eli Moschcowitz in 1924 after autopsy of a 16-year-old girl revealed hyaline thrombi in terminal arterioles and capillaries of multiple organs. 2
The transformation in outcomes is remarkable: TTP was nearly universally fatal until the 1970s, but survival now exceeds 95% with modern treatment. 2 This dramatic improvement resulted from decades of collaborative research identifying ADAMTS13 deficiency as the pathophysiological cornerstone and developing targeted therapies including plasma exchange, immunosuppression, caplacizumab, and recombinant ADAMTS13. 2
Key Clinical Pitfalls
TTP is difficult to distinguish from other thrombotic microangiopathies (TMAs) clinically. In one retrospective study, primary TMA occurred in only 6% of cases—most TMA was secondary to pregnancy, infection, drugs, malignancies, or transplantation. 2 This underscores the importance of ADAMTS13 testing to differentiate true TTP from other TMAs.
ADAMTS13 deficiency alone may not be sufficient to cause acute TTP episodes—environmental triggers or additional genetic predisposition may be required to initiate disease manifestation. 2 This explains why some patients with cTTP remain asymptomatic until adulthood despite lifelong enzyme deficiency.